Pediatric Claim For Guerbet’s Imaging Agent Dotarem Questioned By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
In advisory committee briefing documents, agency reviewers cite limitations in gadoterate’s pediatric experience, particularly among patients two years of age and younger. This is the key population that would differentiate Dotarem from other gadolinium-based contrast agents already on the market.